Thank you, Jan.
detailed financial on highlights look quarter third at more our starting Slide a take X. Let's
mentioned, reported on was flat total $XXX third last revenues were the organic an Jan to compared million, X.X% approximately year. basis As basis a and quarter's on approximately which down
Our adjusted for XXXX. quarter EPS to compared was $X.XX, down XX% the
along quarter, revenue prior versus in XXX year As as basis unfavorable were down impact for revenue. P&L, Gross skin from the by such we inefficiencies gross offset XX% scrap, margin. including margins Boston higher XXXX. with was gross look third down by partially the mix points impacted This margins manufacturing XXXX the on lower were
margins maintaining $XX.X compared to margins in we basis XXXX, the resolve and EBITDA investments of shipping points for infrastructure cash XX.X%, million. reflecting in temporary decrease key gross the XXX Operating impact quarter hold. adjusted the Our was flow down while third R&D were and commercial the
supply that Reported If in quarter third and set normal in access highlights on call. in monitoring basis been Dural third the the a you CSS from the organic have temporary holds and and third prior Neurosurgery CSS These management in detail. were in year. resolved to basis organic an our an sales July X% challenges largely XX% and hold our XX.X% turn we due revenues CSS discussed the examine to July expectations repair in shipping and basis, on Slide line remarks we shipping are in within X, our $XXX Global the [ on our holds up earlier with quarter in remaining more largely guidance. quarter and during ] million, for reported down declined revenue we'll the
decline Neurosurgery disposables. driven and Energy, offset Advanced in CUSA growth in The by partially was capital mid-single-digit by
Our ENT organic third for the quarter. X.X% growth business saw
close X. took remain ] for ENT April only of the the XX delivered future $XX the reported the ENT instruments Acclarent will in million. of about growth approximately following and a growth reflect acquisition, the the a first reminder, We the of potential pleased on which with Acclarent our As months organic the segment MicroFrance place reporting On segment. excited [ ENT basis, revenues integration
double growth For the capital low capital. CUSA sales by and double-digit the relaunch, third Clarity up high in growth low our single-digit driven were CereLink quarter, -- digits,
capital global to continue strong Our to remains well and deliver growth. positioned funnel robust
We saw due with primarily X.X% timing. strong along to Turning order Instruments. demand to growth
affected quarter. we international low customer CSS, the our results business to temporary our to within attributable the double-digit hold. shipping quarter, holds the in to meet Shifting decline demand mostly a These for ability saw
in for the business. However, our prospects international growth we remain confident
on X. on a organic were on reported down Tissue X.X% an Moving basis segment to our million, prior Technologies compared Technologies year. sales Slide to basis Tissue X.X% and the $XXX
the demand prior to not in down year from comparison. impact mostly meet production return in and for X.X%. Wound Skin Integra the was Reconstruction were year-over-year challenging Sales Excluding fully did down product manufactured organic us allow a Boston, of shortfalls because growth
We to which have revenue to outpace offset through remainder Wound strong ramp the low that The quarter. run the for Skin growth Reconstruction to expect continued Skin Integra in of from acquisition. model the growth fourth production the for DuraSorb, headwind double-digit rate the Integra continues and third partially including to quarter was franchise, across return deal historical in by
high by single low Overall, saw demonstrating were demand. the and also sales growth union MicroMatrix to XX% continued platform last double-digit strong We digits, platform. label approximately of due order UBM up our compared [ favorable grew Private to in year ] timing. Cytal
Technologies due Finally, were digits Skin sales Integra Tissue shortages. to the production international mid-double in down
turn you flow. X, will capital our Slide to If cash balance discuss and I structure sheet,
cash driven flow primarily XX.X% the million, and million referenced During cash was by was shipping shortages continued XX-month of a the quarter, in $XX.X $X.X previous cash the production and and basis. flow hold operating remarks Free on in conversion trailing flow impact was negative our investments free CapEx. revenue
As debt was our Xx. leverage billion XX, and net ratio of September consolidated $X.X was total
Integra for business liquidity bringing range facility. quarter. million benefit coming in Neurosurgery our company with shipping the on our most from ratio revolving rates resolving credit and $XXX short-term under of target available X.X had run the back immediate are revenue the in cash investments historical to billion, total and including to our in $X.X the and holds focused remainder Skin within consolidated our The We fourth X.Xx returning leverage of
would prepare If and to of XX. our a points for end as like Slide key capital you structure sheet approach balance we XXXX. and highlight few turn the We about to XXXX
our make we our focused we essential strength bank strategies. liquidity, cash in improving long-term including confident sheet facility flow the on are and investments operations remain the While flexibility to and we growth balance our have generation, in
ratio leverage the EBITDA Acclarent stock-based Just the impact in consolidated of reminder, acquisition. compensation the a both pro forma calculating add-backs for as includes used our and
XXXX. We And under using room due revolver. to credit existing have term, repayment repay the in fund our convertible bond quarter short of our we facility the are sufficient the our in to coming third likely
end interest disclosed existing as million low of have rate debt in XX-Q, the the range will $XXX approximately rate X% With fixed in of we through our our XXXX. swaps,
to rate work in We maintain will monitor to continue capital sufficient our liquidity the and structure. environment
quarter Slide adjusted share the you revenue fourth XXXX. XX, If turn provide I our to will year consolidated earnings for full and guidance per and
expect XX.X% in organic growth we X.X%. to XX.X% quarter, and the X% to revenues For range growth million, representing range to million of the $XXX reported of an fourth of $XXX range a
seasonality. guidance our resolution the production us quarter in call, quarter. Our be historical Integra run they rate fourth to of normal revenue sequential for holds step-up holds incremental partially second the offset in implemented fourth step-up the shipping This revenue reflects the quarter Skin by majority allowing will and have driven sequential meet by of a of fourth identified in quarter revenue the quality the we on
For the billion, compliance X.X% X.X% and investments for full representing the associated estimate full an be XXXX, basis organic plan. year, the minus to the impact billion growth reflecting implementation $X.XXX to We range revenues to X%. with forecasted to approximately and minus XXX the gross the year in X% of master decline range in challenges, margin $X.XXX the of approximate of costs supply in reported of are growth of point
For the to quarter, range share the $X.XX of expect per adjusted year. to EPS we full for $X.XX the in and $X.XX be fourth to $X.XX
Finally, the on for count our key reference. Slide assumed for see assumption and XX, considerations summary a rates, rates you in of tax share FX and our will guidance guidance
the closing his to turn remarks. for call Jan now will I over